Multiple Pharmaceutical Companies File Appeals Over Pricing in China's Ninth Batch of National Drug Procurement

On November 13, the Shanghai Sunshine Pharmaceutical Procurement Network released the "Public Announcement of the Proposed Winning Results for the Centralized Procurement of Fulvestrant Injection in China."

Announcement: From November 7 to 9, during the public announcement period of the proposed winning results of the national centralized drug procurement,Some companies raised price appeal opinions,After research, the proposed winning results of fulvestrant injection are hereby re-announced.

The results showed,CHIATAI TIANQING, Jiangsu Hosen, Shandong New Era, Qilu Pharmaceutical, Hangzhou Jiuyuan Gene, Sichuan Huiyu PharmaceuticalThe prices of fulvestrant injection (5ml:0.25g*2 vials/box) are: 302.6 yuan, 306 yuan, 332 yuan, 511 yuan, 533.72 yuan, and 572 yuan, respectively.

Jianshi Bureau found that,Compared with the previously announced prices, the winning prices of all companies have increased by 1 yuan.

Fulvestrant Injection is a breast cancer treatment drug, with sales exceeding 900 million yuan in public medical institutions in China in 2022. Before this centralized procurement, the medical insurance payment price for AstraZeneca's original drug was 2,306 yuan, while domestically produced products were close to 2,000 yuan.

In other words,The price of Fulvestrant Injection dropped nearly 90% after the ninth round of centralized procurement.